{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:09:15Z","timestamp":1778843355549,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["FP-1605\\u201308753"],"award-info":[{"award-number":["FP-1605\\u201308753"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["08753"],"award-info":[{"award-number":["08753"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["FP-1605"],"award-info":[{"award-number":["FP-1605"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.msard.2020.102398","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T22:14:15Z","timestamp":1594678455000},"page":"102398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Ocrelizumab exposure in the second trimester of pregnancy without neonatal B-cell depletion"],"prefix":"10.1016","volume":"45","author":[{"given":"Mary","family":"Rolfes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Rutatangwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5188-0157","authenticated-orcid":false,"given":"Emmanuelle","family":"Waubant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0090-597X","authenticated-orcid":false,"given":"Kristen M.","family":"Krysko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.msard.2020.102398_bib0007","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1212\/WNL.0000000000005065","article-title":"Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era","volume":"90","author":"Alroughani","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2020.102398_bib0003","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJM199807303390501","article-title":"Rate of pregnancy-related relapse in multiple sclerosis","volume":"339","author":"Confavreux","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102398_bib0014","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJM198712033172306","article-title":"B Lymphocytes","volume":"317","author":"Cooper","year":"1987","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2020.102398_bib0009","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","article-title":"Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD","volume":"5","author":"Das","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.msard.2020.102398_bib0013","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/10408444.2011.653487","article-title":"The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy","volume":"42","author":"DeSesso","year":"2012","journal-title":"Crit. Rev. Toxicol."},{"issue":"9","key":"10.1016\/j.msard.2020.102398_bib0015","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMsa1506575","article-title":"Declines in unintended pregnancy in the United States, 2008-2011","volume":"374","author":"Finer","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102398_bib0011","unstructured":"Genentech. Ocrevus (ocrelizumab) [package insert]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761053s018lbl.pdf. Revised July 2019. Accessed Dec 10, 2019."},{"issue":"10","key":"10.1016\/j.msard.2020.102398_bib0016","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1055\/s-0032-1316440","article-title":"Neonatal effects of magnesium sulfate given to the mother","volume":"29","author":"Ghanavati-Abbassi","year":"2012","journal-title":"Am. J. Perinatol."},{"key":"10.1016\/j.msard.2020.102398_bib0002","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jnnp.2009.187666","article-title":"Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression","volume":"81","author":"Gheuens","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2020.102398_bib0004","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1471-2377-12-124","article-title":"Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentic study","volume":"12","author":"Giannini","year":"2012","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2020.102398_bib0001","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neuro."},{"issue":"2","key":"10.1016\/j.msard.2020.102398_bib0010","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1212\/NXI.0000000000000542","article-title":"Rituximab during pregnancy in neuromyelitis optica: A case report","volume":"6","author":"Miranda-Acu\u00f1a","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102398_bib0012","series-title":"Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)","article-title":"Pregnancy Outcomes in Patients Treated with Ocrelizumab","author":"Oreja-Guevara","year":"2019"},{"issue":"10","key":"10.1016\/j.msard.2020.102398_bib0006","first-page":"e823","article-title":"Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks","volume":"90","author":"Portaccio","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2020.102398_bib0008","doi-asserted-by":"crossref","first-page":"e734","DOI":"10.1212\/NXI.0000000000000734","article-title":"Rituximab, MS, and Pregnancy","volume":"7","author":"Smith","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.msard.2020.102398_bib0005","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/1352458516634872","article-title":"Interferon-beta exposure during first trimester is safe in women with multiple sclerosis - A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry","volume":"22","author":"Thiel","year":"2016","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820304739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820304739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:27:54Z","timestamp":1778840874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820304739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":16,"alternative-id":["S2211034820304739"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102398","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocrelizumab exposure in the second trimester of pregnancy without neonatal B-cell depletion","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102398","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102398"}}